The current treatment of choice for Her2+ breast cancer encompasses the use of the humanized anti-Her2 mAbs trastuzumab and pertuzumab [36], which have recently been demonstrated to be more effective when co-administered [10]. This evidence concerns the gene ERBB2 and breast cancer.